Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss. The company is also developing AM-125 for the treatment of vestibular disorders; and other pre-clinical stage products comprising AM-102 and AM-123. It has a collaboration and license agreement with Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, as well as drug delivery devices and formulations for local administration of therapeutic substances to the inner ear for the treatment of ear disorders. The company was formerly known as Auris Medical AG and changed its name to Auris Medical Holding AG in April 2014. Auris Medical Holding AG was founded in 1998 and is headquartered in Zug, Switzerland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone41-41-729-7194
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees9
Next Earnings Date5/21/2019 (Estimated)
OptionableNot Optionable
Auris Medical (NASDAQ:EARS) Frequently Asked Questions
What is Auris Medical's stock symbol?
Auris Medical trades on the NASDAQ under the ticker symbol "EARS."
How were Auris Medical's earnings last quarter?
Auris Medical Holding Ltd (NASDAQ:EARS) released its quarterly earnings results on Thursday, March, 14th. The biotechnology company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.01. View Auris Medical's Earnings History.
When is Auris Medical's next earnings date?
What price target have analysts set for EARS?
2 brokerages have issued 12 month target prices for Auris Medical's stock. Their forecasts range from $2.50 to $5.00. On average, they anticipate Auris Medical's stock price to reach $3.75 in the next twelve months. This suggests a possible upside of 1,109.7% from the stock's current price. View Analyst Price Targets for Auris Medical.
What is the consensus analysts' recommendation for Auris Medical?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Auris Medical in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Auris Medical.
Has Auris Medical been receiving favorable news coverage?
News headlines about EARS stock have trended somewhat positive on Monday, InfoTrie reports. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Auris Medical earned a news impact score of 1.7 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an impact on the company's share price in the immediate future.
Who are some of Auris Medical's key competitors?
Some companies that are related to Auris Medical include Advanced Accelerator Application (AAAP), Affymax (AFFY), American Oriental Bioengineering (AOBI), Aralez Pharmaceuticals (ARLZ), ARMO Biosciences (ARMO), Bohai Pharmaceuticals Group (BOPH), Cardiome Pharma (CRME), Concordia International (CXRXD), Concordia International (CXRX), Depomed (DEPO), Egalet (EGLT), Eleven Biotherapeutics (EBIO), Epirus Biopharmaceuticals (EPRSQ), ERBA Diagnostics (ERBA) and FutureWorld (FWDG).
What other stocks do shareholders of Auris Medical own?
Who are Auris Medical's key executives?
Auris Medical's management team includes the folowing people:
- Dr. Thomas Meyer, Founder, Chairman, CEO & MD (Age 51)
- Mr. Hernan Levett C.P.A., CPA, Chief Financial Officer (Age 43)
- Colleen A. DeVries, SVP of Cogency Global Inc.
Who are Auris Medical's major shareholders?
Auris Medical's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Wedbush Securities Inc. (0.45%).
Which institutional investors are buying Auris Medical stock?
EARS stock was bought by a variety of institutional investors in the last quarter, including Wedbush Securities Inc..
How do I buy shares of Auris Medical?
Shares of EARS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Auris Medical's stock price today?
One share of EARS stock can currently be purchased for approximately $0.31.
How big of a company is Auris Medical?
Auris Medical has a market capitalization of $11.62 million. The biotechnology company earns $-11,750,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. Auris Medical employs 9 workers across the globe.
What is Auris Medical's official website?
How can I contact Auris Medical?
Auris Medical's mailing address is BAHNHOFSTRASSE 21, ZUG V8, 6300. The biotechnology company can be reached via phone at 41-41-729-7194 or via email at [email protected]
MarketBeat Community Rating for Auris Medical (NASDAQ EARS)
MarketBeat's community ratings are surveys of what our community members think about Auris Medical and other stocks. Vote "Outperform" if you believe EARS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EARS will underperform the S&P 500 over the long term. You may vote once every thirty days.
